Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma.

Duffaud F, Egerer G, Ferrari S, Rassam H, Boecker U, Bui-Nguyen B.

Eur J Cancer. 2012 Mar;48(4):564-70. doi: 10.1016/j.ejca.2011.12.015. Epub 2012 Jan 12.

PMID:
22243773
2.

Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.

Robert NJ, Conkling PR, O'Rourke MA, Kuefler PR, McIntyre KJ, Zhan F, Asmar L, Wang Y, Shonukan OO, O'Shaughnessy JA.

Breast Cancer Res Treat. 2011 Feb;126(1):101-8. doi: 10.1007/s10549-010-1286-0. Epub 2010 Dec 25.

PMID:
21188632
3.

Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer.

Miller KD, Picus J, Blanke C, John W, Clark J, Shulman LN, Thornton D, Rowinsky E, Loehrer PJ Sr.

Ann Oncol. 2000 Jan;11(1):101-3.

4.

A phase II trial of pemetrexed in patients with metastatic renal cancer.

Thödtmann R, Sauter T, Weinknecht S, Weissbach L, Blatter J, Ohnmacht U, Hanauske A.

Invest New Drugs. 2003 Aug;21(3):353-8.

PMID:
14578684
6.

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.

Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, Obasaju CK, Wang Y, Nicol SJ, Kaufman DS.

J Clin Oncol. 2006 Jul 20;24(21):3451-7.

7.

A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.

Dittrich C, Petruzelka L, Vodvarka P, Gneist M, Janku F, Kysela T, Melemed A, Latz J, Simms L, Krejcy K.

Clin Cancer Res. 2006 Dec 1;12(23):7071-8.

8.

Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer.

O'Shaughnessy JA, Clark RS, Blum JL, Mennel RG, Snyder D, Ye Z, Liepa AM, Melemed AS, Yardley DA.

Clin Breast Cancer. 2005 Jun;6(2):143-9.

PMID:
16001992
9.

Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.

[No authors listed]

Prescrire Int. 2005 Dec;14(80):212-4.

PMID:
16400741
10.

Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment: phase II study.

Llombart-Cussac A, Theodoulou M, Rowland K, Clark RS, Nakamura T, Carrasco E, Cruciani G.

Clin Breast Cancer. 2006 Dec;7(5):380-5.

PMID:
17239262
11.

A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer.

Miles DW, Smith IE, Coleman RE, Calvert AH, Lind MJ.

Eur J Cancer. 2001 Jul;37(11):1366-71.

PMID:
11435066
12.

Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy.

Zhang Y, Zhao L, Huang P, Wu J, Wang F, Huang Y, Zhang L.

Cancer Chemother Pharmacol. 2012 Oct;70(4):611-5. Epub 2012 Aug 19.

PMID:
22903536
13.

Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial.

Goedhals L, van Wiyk AL, Smith BL, Fourie SJ.

Int J Gynecol Cancer. 2006 May-Jun;16(3):1172-8.

PMID:
16803502
14.

A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma.

Cohn AL, Myers JW, Mamus S, Deur C, Nicol S, Hood K, Khan MM, Ilegbodu D, Asmar L.

Invest New Drugs. 2008 Aug;26(4):381-6. doi: 10.1007/s10637-008-9124-5. Epub 2008 Feb 28.

PMID:
18305899
15.

Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.

Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, Waggoner SE, Boardman CH.

J Clin Oncol. 2009 Jun 1;27(16):2686-91. doi: 10.1200/JCO.2008.19.2963. Epub 2009 Mar 30.

16.

Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer.

Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ, Ackland SP.

Ann Oncol. 2002 May;13(5):737-41.

17.

A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer.

Garin A, Manikhas A, Biakhov M, Chezhin M, Ivanchenko T, Krejcy K, Karaseva V, Tjulandin S.

Breast Cancer Res Treat. 2008 Jul;110(2):309-15. Epub 2007 Sep 13.

PMID:
17851759
18.

Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma.

Raizer JJ, Rademaker A, Evens AM, Rice L, Schwartz M, Chandler JP, Getch CC, Tellez C, Grimm SA.

Cancer. 2012 Aug 1;118(15):3743-8. doi: 10.1002/cncr.26709. Epub 2011 Dec 16.

19.

ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study.

Smit EF, Mattson K, von Pawel J, Manegold C, Clarke S, Postmus PE.

Ann Oncol. 2003 Mar;14(3):455-60.

20.

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck.

Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, Lefebvre JL, Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R, Latz J, Schneider M.

Br J Cancer. 2001 Sep 1;85(5):649-55.

Items per page

Supplemental Content

Write to the Help Desk